John Callaghan

  • 3258 Citations
  • 22 h-Index
1975 …2019
If you made any changes in Pure, your changes will be visible here soon.

Publications 1975 2019

  • 3258 Citations
  • 22 h-Index
  • 56 Article
2019
2 Citations (Scopus)

Gender Differences in Demographic and Health Characteristics of the Million Veteran Program Cohort

VA Million Veteran Program, Jun 25 2019, In : Women's Health Issues. 29, p. S56-S66

Research output: Contribution to journalArticle

Open Access
Veterans
gender-specific factors
Demography
Health
health
1 Citation (Scopus)

Response to Gammal et al

for the VHA Clinical Pharmacogenetics Subcommittee, Jan 1 2019, (Accepted/In press) In : Genetics in Medicine.

Research output: Contribution to journalArticle

2018
3 Citations (Scopus)

Alcohol Consumption and Risk of Coronary Artery Disease (from the Million Veteran Program)

VA Million Veteran Program, May 15 2018, In : American Journal of Cardiology. 121, 10, p. 1162-1168 7 p.

Research output: Contribution to journalArticle

Veterans
Alcohol Drinking
Coronary Artery Disease
Alcohols
Confidence Intervals
5 Citations (Scopus)

Association of interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: A phenome - Wide association study

Cai, T., Zhang, Y., Ho, Y. L., Link, N., Sun, J., Huang, J., Cai, T. A., Damrauer, S., Ahuja, Y., Honerlaw, J., Costa, L., Schubert, P., Hong, C., Gagnon, D., Sun, Y., Sun, Y. V., Gaziano, J. M., Wilson, P., Cho, K., Tsao, P. & 82 others, O'Donnell, C. J., Liao, K. P., Gaziano, M. J., Ramoni, R., Breeling, J., Chang, K. M., Huang, G., Muralidhar, S., Tsao, P. S., Moser, J., Whitbourne, S. B., Brewer, J. V., Concato, J., Warren, S., Argyres, D. P., Stephens, B., Brophy, M. T., Humphries, D. E., Do, N., Shayan, S., Nguyen, X. M. T., Pyarajan, S., Hauser, E., Zhao, H., McArdle, R., Dellitalia, L., Harley, J., Whittle, J., Beckham, J., Wells, J., Gutierrez, S., Gibson, G., Kaminsky, L., Villareal, G., Xu, J., Hamner, M., Haddock, K. S., Bhushan, S., Iruvanti, P., Godschalk, M., Ballas, Z., Buford, M., Mastorides, S., Klein, J., Ratcliffe, N., Florez, H., Swann, A., Murdoch, M., Sriram, P., Kinlay, S., Yeh, S. S., Washburn, R., Jhala, D., Aguayo, S., Cohen, D., Sharma, S., Callaghan, J., Oursler, K. A., Whooley, M., Ahuja, S., Gutierrez, A., Schifman, R., Greco, J., Rauchman, M., Servatius, R., Oehlert, M., Wallbom, A., Fernando, R., Morgan, T., Stapley, T., Sherman, S., Anderson, G., Sonel, E., Boyko, E., Meyer, L., Gupta, S., Fayad, J., Hung, A., Lichy, J., Hurley, R., Robey, B. & Striker, R., Sep 1 2018, In : JAMA Cardiology. 3, 9, p. 849-857 9 p.

Research output: Contribution to journalArticle

Interleukin-6 Receptors
Cardiovascular Diseases
Single Nucleotide Polymorphism
Veterans
Aortic Aneurysm
6 Citations (Scopus)

DASH score and subsequent risk of coronary artery disease: The findings from million veteran program

on behalf of the VA Million Veteran Program, May 1 2018, In : Journal of the American Heart Association. 7, 9, e008089.

Research output: Contribution to journalArticle

Veterans
Coronary Artery Disease
Hypertension
Diet
Hydroxymethylglutaryl-CoA Reductase Inhibitors
6 Citations (Scopus)

Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee

for the VHA Clinical Pharmacogenetics Subcommittee, Jun 1 2018, (Accepted/In press) In : Genetics in Medicine. p. 1-9 9 p.

Research output: Contribution to journalArticle

Veterans Health
United States Department of Veterans Affairs
Pharmacogenetics
Health Policy
clopidogrel
2016
50 Citations (Scopus)

CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Saito, Y., Stamp, L. K., Caudle, K. E., Hershfield, M. S., McDonagh, E. M., Callaghan, J., Tassaneeyakul, W., Mushiroda, T., Kamatani, N., Goldspiel, B. R., Phillips, E. J., Klein, T. E. & Lee, M. T. M., Jan 1 2016, In : Clinical Pharmacology and Therapeutics. 99, 1, p. 36-37 2 p.

Research output: Contribution to journalArticle

Pharmacogenetics
Guidelines
Research
Allopurinol
HLA-B Antigens
18 Citations (Scopus)

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial

Eadon, M., Desta, Z., Levy, K., Decker, B., Pierson, R., Pratt, V., Callaghan, J., Rosenman, M., Carpenter, J., Holmes, A., Mcdonald, C., Benson, E., Patil, A., Vuppalanchi, R., Gufford, B., Dave, N., Robarge, J., Hyder, M., Haas, D., Kreutz, R. & 3 others, Dexter, P., Skaar, T. & Flockhart, D., 2016, (Accepted/In press) In : Clinical Pharmacology and Therapeutics.

Research output: Contribution to journalArticle

Safety-net Providers
Credentialing
Pharmacogenetics
Vulnerable Populations
Poverty
4 Citations (Scopus)

Inhibition of cytochrome P450 2B6 activity by voriconazole profiled using efavirenz disposition in healthy volunteers

Desta, Z., Metzger, I. F., Thong, N., Lu, J. B. L., Callaghan, J., Skaar, T., Flockhart, D. A. & Galinsky, R. E., Nov 1 2016, In : Antimicrobial Agents and Chemotherapy. 60, 11, p. 6813-6822 10 p.

Research output: Contribution to journalArticle

efavirenz
Healthy Volunteers
Reverse Transcriptase Inhibitors
Cytochrome P-450 CYP2B6
Voriconazole
2014
98 Citations (Scopus)

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing

Caudle, K. E., Rettie, A. E., Whirl-Carrillo, M., Smith, L. H., Mintzer, S., Lee, M. T., Klein, T. E. & Callaghan, J., Sep 17 2014, In : Clinical Pharmacology and Therapeutics. 96, 5, p. 542-548 7 p.

Research output: Contribution to journalArticle

HLA-B Antigens
Pharmacogenetics
Phenytoin
Anticonvulsants
Genotype
302 Citations (Scopus)

Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update

Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shen, D. D., Callaghan, J., Sadhasivam, S., Prows, C. A., Kharasch, E. D. & Skaar, T., 2014, In : Clinical Pharmacology and Therapeutics. 95, 4, p. 376-382 7 p.

Research output: Contribution to journalArticle

Codeine
Cytochrome P-450 CYP2D6
Pharmacogenetics
Genotype
Guidelines
14 Citations (Scopus)

PharmGKB summary: Uric acid-lowering drugs pathway, pharmacodynamics

McDonagh, E. M., Thorn, C. F., Callaghan, J., Altman, R. B. & Klein, T. E., 2014, In : Pharmacogenetics and Genomics. 24, 9, p. 464-476 13 p.

Research output: Contribution to journalArticle

Gout Suppressants
Gene Expression Regulation
Uric Acid
Pharmaceutical Preparations
4 Citations (Scopus)

Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers

Metzger, I. F., Quigg, T. C., Epstein, N., Aregbe, A. O., Thong, N., Callaghan, J., Flockhart, D. A., Nguyen, A. T., Stevens, C. K., Gupta, S. & Desta, Z., Dec 1 2014, In : Current Therapeutic Research - Clinical and Experimental. 76, p. 64-69 6 p.

Research output: Contribution to journalArticle

efavirenz
Bilirubin
Healthy Volunteers
Drug Interactions
Hemoglobins
2013
119 Citations (Scopus)

Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-b genotype and allopurinol dosing

Hershfield, M. S., Callaghan, J., Tassaneeyakul, W., Mushiroda, T., Thorn, C. F., Klein, T. E. & Lee, M. T. M., Feb 2013, In : Clinical Pharmacology and Therapeutics. 93, 2, p. 153-158 6 p.

Research output: Contribution to journalArticle

Allopurinol
Pharmacogenetics
HLA Antigens
Genotype
Guidelines
2012
243 Citations (Scopus)

Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype

Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J., Kharasch, E. D. & Skaar, T., Feb 2012, In : Clinical Pharmacology and Therapeutics. 91, 2, p. 321-326 6 p.

Research output: Contribution to journalArticle

Codeine
Cytochrome P-450 CYP2D6
Pharmacogenetics
Genotype
Guidelines
63 Citations (Scopus)

Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

Duke, J. D., Han, X., Wang, Z., Subhadarshini, A., Karnik, S. D., Li, X., Hall, S. D., Jin, Y., Callaghan, J., Overhage, M. J., Flockhart, D. A., Strother, R. M., Quinney, S. & Li, L., Aug 2012, In : PLoS Computational Biology. 8, 8, e1002614.

Research output: Contribution to journalArticle

Drug interactions
Electronic medical equipment
drug interactions
Electronic Health Records
muscular diseases
2007
56 Citations (Scopus)

QT effects of duloxetine at supratherapeutic doses: A placebo and positive controlled study

Zhang, L., Chappell, J., Gonzales, C. R., Small, D., Knadler, M. P., Callaghan, J., Francis, J. L., Desaiah, D., Leibowitz, M., Ereshefsky, L., Hoelscher, D., Leese, P. T. & Derby, M., Mar 2007, In : Journal of Cardiovascular Pharmacology. 49, 3, p. 146-153 8 p.

Research output: Contribution to journalArticle

Placebos
Duloxetine Hydrochloride
Cross-Over Studies
Healthy Volunteers
Electrocardiography
23 Citations (Scopus)

The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate

Derby, M. A., Zhang, L., Chappell, J. C., Gonzales, C. R., Callaghan, J., Leibowitz, M., Ereshefsky, L., Hoelscher, D., Leese, P. T. & Mitchell, M. I., Jun 2007, In : Journal of Cardiovascular Pharmacology. 49, 6, p. 384-393 10 p.

Research output: Contribution to journalArticle

Heart Rate
Blood Pressure
Vital Signs
Cross-Over Studies
Duloxetine Hydrochloride
2003
15 Citations (Scopus)

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Forouzesh, B., Takimoto, C. H., Goetz, A., Diab, S., Hammond, L. A., Smetzer, L., Schwartz, G., Gazak, R., Callaghan, J., Von Hoff, D. D. & Rowinsky, E. K., Nov 15 2003, In : Clinical Cancer Research. 9, 15, p. 5540-5549 10 p.

Research output: Contribution to journalArticle

N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea
Appointments and Schedules
Pharmacokinetics
Neoplasms
Maximum Tolerated Dose
619 Citations (Scopus)

The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

Bjornsson, T. D., Callaghan, J., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., Kumar, G., McLeod, J., Obach, R. S., Roberts, S., Roe, A., Shah, A., Snikeris, F., Sullivan, J. T., Tweedie, D., Vega, J. M. & 2 others, Walsh, J. & Wrighton, S. A., Jul 1 2003, In : Drug Metabolism and Disposition. 31, 7, p. 815-832 18 p.

Research output: Contribution to journalArticle

Drug interactions
Drug Interactions
Industry
Pharmaceutical Preparations
Practice Guidelines
249 Citations (Scopus)

The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective

Bjornsson, T. D., Callaghan, J., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., Kumar, G., McLeod, J., Obach, S. R., Roberts, S., Roe, A., Shah, A., Snikeris, F., Sullivan, J. T., Tweedie, D., Vega, J. M. & 2 others, Walsh, J. & Wrighton, S. A., May 1 2003, In : Journal of Clinical Pharmacology. 43, 5, p. 443-469 27 p.

Research output: Contribution to journalArticle

Drug Interactions
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Industry
Clinical Pharmacology
2002
51 Citations (Scopus)

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity

Belle, D. J., Callaghan, J., Gorski, J. C., Maya, J. F., Mousa, O., Wrighton, S. A. & Hall, S. D., 2002, In : British Journal of Clinical Pharmacology. 53, 1, p. 67-74 8 p.

Research output: Contribution to journalArticle

Norgestrel
Cytochrome P-450 CYP3A
Ethinyl Estradiol
Midazolam
Oral Contraceptives
2000
218 Citations (Scopus)

Confidence interval criteria for assessment of dose proportionality

Smith, B. P., Vandenhende, F. R., DeSante, K. A., Farid, N. A., Welch, P. A., Callaghan, J. & Forgue, S. T., 2000, In : Pharmaceutical Research. 17, 10, p. 1278-1283 6 p.

Research output: Contribution to journalArticle

Pharmacokinetics
Confidence Intervals
Acoustic waves
1999
405 Citations (Scopus)

Olanzapine: Pharmacokinetic and pharmacodynamic profile

Callaghan, J., Bergstrom, R. F., Ptak, L. R. & Beasley, C. M., 1999, In : Clinical Pharmacokinetics. 37, 3, p. 177-193 17 p.

Research output: Contribution to journalArticle

olanzapine
Pharmacokinetics
Imipramine
Glucuronides
Alcohols
1998
18 Citations (Scopus)

Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men

Macias, W. L., Bergstrom, R. F., Cerimele, B. J., Kassahun, K., Tatum, D. E. & Callaghan, J., Nov 1998, In : Pharmacotherapy. 18, 6 I, p. 1237-1248 12 p.

Research output: Contribution to journalArticle

olanzapine
Aminophylline
Theophylline
Pharmacokinetics
Cimetidine
1997
191 Citations (Scopus)

Disposition and biotransformation of the antipsychotic agent olanzapine in humans

Kassahun, K., Mattiuz, E., Nyhart, E., Obermeyer, B., Gillespie, T., Murphy, A., Goodwin, R. M., Tupper, D., Callaghan, J. & Lemberger, L., Jan 1997, In : Drug Metabolism and Disposition. 25, 1, p. 81-93 13 p.

Research output: Contribution to journalArticle

olanzapine
Biotransformation
Antipsychotic Agents
Glucuronides
Metabolites
30 Citations (Scopus)

Olanzapine: Interaction study with imipramine

Callaghan, J., Cerimele, B. J., Kassahun, K. J., Nyhart, E. H., Hoyes-Beehler, P. J. & Kondraske, G. V., Oct 1997, In : Journal of Clinical Pharmacology. 37, 10, p. 971-978 8 p.

Research output: Contribution to journalArticle

olanzapine
Imipramine
Cytochrome P-450 CYP2D6
Desipramine
Vital Signs
2 Citations (Scopus)

Olanzapine and warfarin drug interaction

Maya, J. F., Callaghan, J., Bergstrom, R. F., Cerimele, B. J., Kassahun, K., Nyhart, E. H. & Brater, D. C., 1997, In : Clinical Pharmacology and Therapeutics. 61, 2, p. 182 1 p.

Research output: Contribution to journalArticle

olanzapine
Warfarin
Drug Interactions
Pharmacokinetics
High Pressure Liquid Chromatography
29 Citations (Scopus)

Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine

Mäenpää, J., Wrighton, S., Bergstrom, R., Cerimele, B., Tatum, D., Hatcher, B. & Callaghan, J., 1997, In : Clinical Pharmacology and Therapeutics. 61, 2, p. 225 1 p.

Research output: Contribution to journalArticle

olanzapine
Fluvoxamine
Pharmacokinetics
Cytochrome P-450 CYP1A2
1990
4 Citations (Scopus)

Disposition in humans of racemic picenadol, an opioid analgesic

Franz, P. M., Anliker, S. L., Callaghan, J., DeSante, K. A., Dhahir, P. H., Nelson, R. L. & Rubin, A., 1990, In : Drug Metabolism and Disposition. 18, 6, p. 968-973 6 p.

Research output: Contribution to journalArticle

picenadol
Opioid Analgesics
Enantiomers
Radioactivity
Plasmas
6 Citations (Scopus)

Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion

Schneck, D. W., Callaghan, J., Bergstrom, R. F., Obermeyer, B. D. & Offen, W. W., Apr 1990, In : Clinical Pharmacology and Therapeutics. 47, 4, p. 499-503 5 p.

Research output: Contribution to journalArticle

Nizatidine
Gastric Acid
Acids
Stomach
Placebos
11 Citations (Scopus)

Role of serum prolactin determination in evaluation of impotent patient

Foster, R., Mulcahy, J. J., Callaghan, J., Crabtree, R. & Brashear, D., 1990, In : Urology. 36, 6, p. 499-501 3 p.

Research output: Contribution to journalArticle

Prolactin
Hyperprolactinemia
Serum
Libido
Erectile Dysfunction
17 Citations (Scopus)

Secretion of nizatidine into human breast milk after single and multiple doses

Obermeyer, B. D., Bergstrom, R. F., Callaghan, J., Knadler, M. P., Golichowski, A. & Rubin, A., Jun 1990, In : Clinical Pharmacology and Therapeutics. 47, 6, p. 724-730 7 p.

Research output: Contribution to journalArticle

Nizatidine
Human Milk
Serum
Half-Life
Milk
1989
46 Citations (Scopus)

Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics

Israel, E., Juniper, E. F., Callaghan, J., Mathur, P. N., Morris, M. M., Dowell, A. R., Enas, G. G., Hargreave, F. E. & Drazen, J. M., 1989, In : American Review of Respiratory Disease. 140, 5, p. 1348-1353 6 p.

Research output: Contribution to journalArticle

LY 171883
Leukotriene Antagonists
Bronchoconstriction
Air
Leukotriene D4
1988
11 Citations (Scopus)

Double-blind comparator trials with pinacidil, a potassium channel opener

Callaghan, J., Goldberg, M. R. & Brunelle, R., 1988, In : Drugs. 36, SUPPL. 7, p. 77-82 6 p.

Research output: Contribution to journalArticle

Pinacidil
Potassium Channels
Antihypertensive Agents
Placebos
Methyldopa
22 Citations (Scopus)

Nizatidine disposition in subjects with normal and impaired renal function

Aronoff, G. R., Bergstrom, R. F., Bopp, R. J., Sloan, R. S. & Callaghan, J., Jun 1988, In : Clinical Pharmacology and Therapeutics. 43, 6, p. 688-695 8 p.

Research output: Contribution to journalArticle

Nizatidine
Renal Insufficiency
Kidney
Healthy Volunteers
Renal Dialysis
1987
22 Citations (Scopus)

Absorption studies of the H2-blocker nizatidine

Knadler, M. P., Bergstrom, R. F., Callaghan, J., Obermeyer, B. D. & Rubin, A., Nov 1987, In : Clinical Pharmacology and Therapeutics. 42, 5, p. 514-520 7 p.

Research output: Contribution to journalArticle

Nizatidine
Biological Availability
Propantheline
Charcoal
Food
42 Citations (Scopus)

A pharmacokinetic profile of nizatidine in man.

Callaghan, J., Bergstrom, R. F., Rubin, A., Chernish, S., Crabtree, R., Knadler, M. P., Obermeyer, B., Offen, W. W., Schneck, D. W. & Aronoff, G., 1987, In : Scandinavian Journal of Gastroenterology, Supplement. 136, p. 9-17 9 p.

Research output: Contribution to journalArticle

Nizatidine
Pharmacokinetics
Meals
Kidney
Pentagastrin
15 Citations (Scopus)

Nizatidine, and H2-receptor antagonist: Disposition and safety in the elderly

Callaghan, J., Rubin, A., Knadler, M. P. & Bergstrom, R. F., 1987, In : Journal of Clinical Pharmacology. 27, 8, p. 618-624 7 p.

Research output: Contribution to journalArticle

Nizatidine
Histamine H2 Receptors
Safety
Kidney
Volunteers
1986
71 Citations (Scopus)

Nizatidine, an H2-blocker. Its metabolism and disposition in man

Knadler, M. P., Bergstrom, R. F., Callaghan, J. & Rubin, A., 1986, In : Drug Metabolism and Disposition. 14, 2, p. 175-182 8 p.

Research output: Contribution to journalArticle

Nizatidine
Metabolism
Radioactivity
Metabolites
Plasmas
1985
27 Citations (Scopus)

Intravenous nizatidine kinetics and acid suppression

Callaghan, J., Bergstrom, R. F., Obermeyer, B. D., King, E. P. & Offen, W. W., Feb 1985, In : Clinical Pharmacology and Therapeutics. 37, 2, p. 162-165 4 p.

Research output: Contribution to journalArticle

Nizatidine
Acids
Gastric Acid
Cimetidine
Intravenous Infusions
1983
4 Citations (Scopus)

Correlation of in vivo and in vitro expression of cell-mediated immunity to mumps skin test antigen

Peterson, B. H., Callaghan, J., Steirnel, L. A. & Epirvette, W. W., 1983, In : Journal of Allergy and Clinical Immunology. 71, 6, p. 612-617 6 p.

Research output: Contribution to journalArticle

Mumps
Lymphocyte Activation
Skin Tests
Cellular Immunity
Antigens
6 Citations (Scopus)

Delayed hypersensitivity to mumps antigen in humans

Callaghan, J., Petersen, B. H., Smith, W. C., Epinette, W. W. & Ransburg, R. C., 1983, In : Clinical Immunology and Immunopathology. 26, 1, p. 102-110 9 p.

Research output: Contribution to journalArticle

Mumps
Delayed Hypersensitivity
Antigens
Skin Tests
Histoplasmin
11 Citations (Scopus)

Effect of cholestyramine and colestipol on the absorption of phenytoin

Callaghan, J., Tsuru, M., Holtzman, J. L. & Hunninghake, D. B., Sep 1983, In : European Journal of Clinical Pharmacology. 24, 5, p. 675-678 4 p.

Research output: Contribution to journalArticle

Colestipol
Cholestyramine Resin
Phenytoin
Anions
Cations
37 Citations (Scopus)

Suppression of mitogen-induced lymphocyte transformation in cigarette smokers

Petersen, B. H., Steimel, L. F. & Callaghan, J., 1983, In : Clinical Immunology and Immunopathology. 27, 1, p. 135-140 6 p.

Research output: Contribution to journalArticle

Phytohemagglutinins
Lymphocyte Activation
Mitogens
Tobacco Products
Antigens
1982

Correlation of in vivo and in vitro expression of cell mediated immunity to mumps skin test antigen

Petersen, B. H., Callaghan, J., Steimel, L. F. & Epinette, W. W., 1982, In : International Journal of Immunopharmacology. 4, 4, p. 372 1 p.

Research output: Contribution to journalArticle

Mumps
Skin Tests
Cellular Immunity
Antigens
In Vitro Techniques

Gastric secretion of histamine after gastrin administration in normal human subjects

Verburg, K. M., Henry, D. P., Callaghan, J. & Bowsher, R. R., 1982, In : Clinical Research. 30, 4

Research output: Contribution to journalArticle

Gastrins
Histamine
Stomach
2 Citations (Scopus)

Picenadol, an opioid with mu- and delta-receptor affinity

Callaghan, J. & Crabtree, R. E., 1982, In : Clinical Research. 30, 4

Research output: Contribution to journalArticle

picenadol
delta Opioid Receptor
mu Opioid Receptor
Opioid Analgesics
1981
15 Citations (Scopus)

Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative

Callaghan, J., Cleary, R. E., Crabtree, R. & Lemberger, L., Jan 5 1981, In : Life Sciences. 28, 1, p. 95-102 8 p.

Research output: Contribution to journalArticle

Pergolide
Galactorrhea
Prolactin
Derivatives
Amenorrhea
5 Citations (Scopus)

CSF perfusion to treat intraventricular penicillin toxicity

Callaghan, J., Ausman, J. I. & Clubb, R., 1981, In : Archives of Neurology. 38, 6, p. 390-391 2 p.

Research output: Contribution to journalArticle

Penicillin G
Meningitis
Methotrexate
Respiratory Insufficiency
Penicillins